AI Summary & Key Takeaways
AI InsightThis review discusses the role, therapeutic potential, and clinical evidence regarding Camellia sinensis L., as a natural source of pancreatic lipase inhibitor in the treatment of obesity will be discussed in the light of clinical data.
📌 3 Key Takeaways
Abstract
Obesity, one of the most common health problems of the 21st century, is defined as a person's body mass index being greater than or equal to 30 kg/m² or greater, and it is rapidly increasing on a global scale and causes complications such as type 2 diabetes, hypertension, cardiovascular diseases, osteoarthritis, non-alcoholic fatty liver disease and chronic kidney disease. It is also associated with many other diseases including depression and some types of cancer. Lipase inhibitors, which target lipases, one of the body fat metabolism enzymes, are used in the treatment of chronic obesity, however, according to the American Food and Drug Administration (FDA) long-term use of these drugs is reported to cause serious side effects. Secondary metabolites and plant extracts isolated from numerous plant species with medicinal uses as natural origin pancreatic lipase inhibitors in the treatment of obesity are recorded in the literature. They limit the absorption of fats into the body by inhibiting pancreatic lipase, and in this way, they complement conventional anti-obesity drugs. This review discusses the role, therapeutic potential, and clinical evidence regarding Camellia sinensis L., as a natural source of pancreatic lipase inhibitor in the treatment of obesity will be discussed in the light of clinical data.